Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Halozyme Therapeutics Inc HALO

Healthcare Biotechnology

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on... see more

Add To Watchlist

Recent & Breaking News (NDAQ:HALO)

Halozyme Appoints New Chief Financial Officer

PR Newswire February 2, 2022

HALOZYME PROVIDES 2022 FINANCIAL GUIDANCE AND OUTLOOK

PR Newswire January 10, 2022

Halozyme to Present Virtually at the 40th Annual J.P. Morgan Health Care Conference

PR Newswire January 4, 2022

HALOZYME APPOINTS NEW GENERAL COUNSEL

PR Newswire December 13, 2021

HALOZYME ANNOUNCES $750 MILLION THREE-YEAR SHARE REPURCHASE PROGRAM

PR Newswire December 9, 2021

Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse

PR Newswire December 1, 2021

Halozyme to Present at Upcoming Investor Conferences

PR Newswire November 18, 2021

Halozyme Reports Third Quarter 2021 Results

PR Newswire November 2, 2021

Halozyme To Host Third Quarter 2021 Financial Results Webcast and Conference Call

PR Newswire October 19, 2021

Halozyme to Participate in the 2021 Cantor Virtual Global Healthcare Conference

PR Newswire September 15, 2021

Halozyme to Present at Wells Fargo 2021 Virtual Healthcare Conference

PR Newswire August 26, 2021

Halozyme Reports Second Quarter 2021 Results

PR Newswire August 9, 2021

Halozyme to Participate in Canaccord Genuity 41st Annual Growth Conference

PR Newswire July 30, 2021

Halozyme To Host Second Quarter 2021 Financial Results Webcast and Conference Call

PR Newswire July 27, 2021

Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse

PR Newswire July 12, 2021

Halozyme Announces Janssen Receives European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-Treated Multiple Myeloma

PR Newswire June 22, 2021

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra long-acting" medicines for HIV

Business Wire June 22, 2021

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV

PR Newswire June 22, 2021

Halozyme Highlights Data Presentations by Collaborators for Therapies Utilizing ENHANZE® at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

PR Newswire June 1, 2021

Halozyme to Present at Upcoming Investor Conferences

PR Newswire May 28, 2021